Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, Scholtes C, Holzmann H, van Bömmel F, Borghi M, Perbellini R, Rimondi A, Farina E, Trombetta E, Manunta M, Porretti L, Prati D, Ceriotti F, Zoulim F, Bertoletti A, Lampertico P. Loglio A, et al. Among authors: scholtes c. J Hepatol. 2022 Feb;76(2):464-469. doi: 10.1016/j.jhep.2021.10.012. Epub 2021 Oct 23. J Hepatol. 2022. PMID: 34699951
Standardized one-step real-time reverse transcription-PCR assay for universal detection and quantification of hepatitis delta virus from clinical samples in the presence of a heterologous internal-control RNA.
Scholtes C, Icard V, Amiri M, Chevallier-Queyron P, Trabaud MA, Ramière C, Zoulim F, André P, Dény P. Scholtes C, et al. J Clin Microbiol. 2012 Jun;50(6):2126-8. doi: 10.1128/JCM.06829-11. Epub 2012 Mar 14. J Clin Microbiol. 2012. PMID: 22422856 Free PMC article.
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.
Virlogeux V, Pradat P, Hartig-Lavie K, Bailly F, Maynard M, Ouziel G, Poinsot D, Lebossé F, Ecochard M, Radenne S, Benmakhlouf S, Koffi J, Lack P, Scholtes C, Uhres AC, Ducerf C, Mabrut JY, Rode A, Levrero M, Combet C, Merle P, Zoulim F. Virlogeux V, et al. Among authors: scholtes c. Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25. Liver Int. 2017. PMID: 28423231
Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.
Halfon P, Scholtès C, Izopet J, Larrat S, Trimoulet P, Zoulim F, Alric L, Métivier S, Leroy V, Ouzan D, de Lédinghen V, Mohamed S, Pénaranda G, Khiri H, Thélu MA, Plauzolles A, Chiche L, Bourlière M, Abravanel F. Halfon P, et al. Among authors: scholtes c. J Hepatol. 2018 Mar;68(3):595-597. doi: 10.1016/j.jhep.2017.09.019. Epub 2017 Oct 4. J Hepatol. 2018. PMID: 28987520 No abstract available.
Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.
Virlogeux V, Berthillon P, Bordes I, Larrat S, Crouy S, Scholtès C, Pradat P, Maynard M, Zoulim F, Leroy V, Chemin I, Trépo C, Petit MA. Virlogeux V, et al. Among authors: scholtes c. Clin Res Hepatol Gastroenterol. 2018 Sep;42(4):313-318. doi: 10.1016/j.clinre.2018.02.002. Epub 2018 Mar 16. Clin Res Hepatol Gastroenterol. 2018. PMID: 29551607
101 results